You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TCR

Showing 26 - 50 of 702
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pediatric Patients, Hematologic Malignancy, Other Hematologic Condition Trial in Aurora (CliniMACS Plus Instrument)

Not yet recruiting
  • Pediatric Patients
  • +2 more
  • CliniMACS Plus Instrument
  • Aurora, Colorado
    Children's Hospital Colorado
Jun 29, 2022

Melanoma, Melanoma, Uveal, Head Neck Cancer Trial in Rotterdam (Adoptive therapy with autologous MC2 TCR T cells)

Recruiting
  • Melanoma
  • +2 more
  • Adoptive therapy with autologous MC2 TCR T cells
  • Rotterdam, Netherlands
    Erasmus Medical Center
Jun 1, 2022

Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))

Completed
  • Hepatocellular Carcinoma
  • TCR-T
  • No intervention and TCR-T (at crossover)
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital, Sun-Yat Sen University
Jun 27, 2022

Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)

Withdrawn
  • Advanced Solid Tumor
  • TCRT-ESO-A2
  • (no location specified)
Aug 31, 2022

Malignant Tumor Trial in Los Angeles (biological, drug, other, radiation, procedure)

Active, not recruiting
  • Malignant Neoplasm
  • aldesleukin
  • +7 more
  • Los Angeles, California
    University of California at Los Angeles (UCLA )
Dec 1, 2022

EBV Emia and EBV Positive PTLD After Allogenic HSCT Trial in Sanhe (EBV-TCR-T cells)

Completed
  • EBV Emia and EBV Positive PTLD After Allogenic HSCT
  • EBV-TCR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Mar 6, 2022

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

Learn How Triple Class Refractory Multiple Myeloma Are Treated

Not yet recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
    • (no location specified)
    Feb 15, 2023

    Advanced Solid Tumor Trial in Bethesda, Boston (STAR0602)

    Recruiting
    • Advanced Solid Tumor
    • Bethesda, Maryland
    • +1 more
    Jan 6, 2023

    TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors Trial in Nanning (KSX01-TCRT injection)

    Recruiting
    • TCR-T Cells
    • +2 more
    • KSX01-TCRT injection
    • Nanning, Guangxi Zhuang Autonomous Region, China
      The first affiliated hospital of Guang Xi medical university
    Mar 31, 2023

    CMV Infection or Reactivation After Allogenic HSCT Trial in Sanhe (CMV-TCR-T cells)

    Recruiting
    • CMV Infection or Reactivation After Allogenic HSCT
    • CMV-TCR-T cells
    • Sanhe, Hebei, China
      Hebei Yanda Ludaopei Hospital
    Jan 29, 2022

    Pediatric Hematologic Malignancies Trial in Saint Louis (Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs

    Not yet recruiting
    • Pediatric Hematologic Malignancies
    • Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jul 20, 2022

    Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia Trial (CliniMACS® device)

    Not yet recruiting
    • Graft Vs Host Disease
    • +5 more
    • CliniMACS® device
    • (no location specified)
    Jul 20, 2023

    Hemoglobinopathy (Disorder), Severe Aplastic Anemia, Bone Marrow Failure Syndrome Trial in Saint Petersburg (Haploidentical

    Recruiting
    • Hemoglobinopathy (Disorder)
    • +2 more
    • Haploidentical Hematopoietic Cell Transplantation
    • Saint Petersburg, Florida
      Johns Hopkins All Children's Hospital
    Sep 13, 2022

    HLA Typing and Tumor Neoantigen Identification forPhase I/II

    Recruiting
    • Ovarian Cancer
    • +5 more
      • Houston, Texas
        MD Anderson Cancer Center
      Jul 27, 2022

      CMV Infection After Allogenic HSCT Trial in Beijing (CMV-TCR-T cells)

      Recruiting
      • CMV Infection After Allogenic HSCT
      • CMV-TCR-T cells
      • Beijing, Beijing, China
        Chinese PLA General Hospital
      Dec 5, 2021

      Papillomavirus Infections, Oropharyngeal Tumors Trial run by the NCI (E7 T-Cell Receptor (TCR))

      Terminated
      Has Results
      • Papillomavirus Infections
      • Oropharyngeal Neoplasms
      • E7 T-Cell Receptor (TCR)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 3, 2022

      Gastric Cancer, Breast Cancer, Cervical Cancer Trial in New Brunswick (KK-LC-1 TCR-T cells, Aldesleukin 720,000 IU/kg IV every

      Not yet recruiting
      • Gastric Cancer
      • +3 more
      • KK-LC-1 TCR-T cells
      • Aldesleukin 720,000 IU/kg IV every eight hours
      • New Brunswick, New Jersey
        Rutgers Cancer Institute of New Jersey
      Jul 30, 2022

      Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

      Recruiting
      • Hepatocellular Carcinoma
      • SCG101
      • PD1/PD-L1 checkpoint inhibitor
      • Beijing, China
      • +3 more
      May 7, 2022

      Solid Tumor Trial in Guangzhou (tumor-specific TCR-T cells, Interleukin-2)

      Recruiting
      • Solid Tumor
      • Guangzhou, Gaungdong, China
        Sun Yat-sen University Cancer Center
      Oct 21, 2021

      Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Cleveland

      Not yet recruiting
      • Allogeneic Stem Cell Transplant Candidate
      • +4 more
      • Cellular therapy product
      • Cleveland, Ohio
        University Hospitals Cleveland Medical Center, Case Comprehensiv
      Jul 1, 2022

      Uterine Cervical Tumors Trial run by the NCI (E7 T-Cell Receptor (TCR))

      Terminated
      Has Results
      • Uterine Cervical Neoplasms
      • E7 T-Cell Receptor (TCR)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Dec 7, 2021

      Advanced Solid Tumors Trial in Chongqing (TC-N201 cells, IL-2, Fludarabine)

      Recruiting
      • Advanced Solid Tumors
      • TC-N201 cells
      • +4 more
      • Chongqing, China
        TCRCure Biopharma Ltd.
      May 25, 2023

      Advanced Solid Tumor Trial in Beijing (YK0901 cells)

      Not yet recruiting
      • Advanced Solid Tumor
      • YK0901 cells
      • Beijing, China
        Department of GI Oncology, Peking University Cancer Hospital
      Jun 27, 2023

      Diffuse Midline Glioma, H3 K27M-Mutant Trial in San Francisco (Cyclophosphamide, Fludarabine, Autologous Anti-H3.3K27M

      Not yet recruiting
      • Diffuse Midline Glioma, H3 K27M-Mutant
      • San Francisco, California
        University of California, San Francisco
      Aug 15, 2022